Syngene International Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/bud0pz0aordnvvrkfnil3uxk.pdf

Key Takeaways


Margin & Cost Structure

Deepak Jain: "Our strong balance sheet and net cash position provide the financial flexibility to invest in key strategic priorities to support our growth."

Clinical Services Breakthrough


Biologics Manufacturing: Correction Now, Capacity Later

Peter Bains: "Our Q2 performance was driven by underlying revenue growth from research services which compensated for the anticipated inventory correction in biologics manufacturing. We are maintaining our annual guidance for revenue for FY26."

Demand Environment & Funding

Peter Bains: "From a broader perspective, the U.S. biotech funding environment is showing early signs of improvement. We continue to monitor trends and maintain agile strategies to adapt quickly as the funding environment evolves."

Sustainability & Operational Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
Annual revenue guidanceMaintain existing FY26 revenue guidanceFY26 full year
EBITDA and PAT margin guidanceMaintain existing FY26 EBITDA and PAT margin guidanceFY26 full year
Bayview facility operationalizationRevalidation, integration and staff recruitment progressing toward operational startH2 FY26
ADC manufacturing capabilityNew GMP bioconjugation suite under construction in Bengaluru biologics facilityNo date given
Peptide and ADC platform investmentDedicated facilities being built for peptides and ADCsNo date given

Key Metrics

MetricQ2 FY26
Revenue from operations₹911 Cr, +2% YoY and +4% QoQ
Reported revenue₹926 Cr, +2% YoY
Reported EBITDA₹215 Cr, -18% YoY
Reported EBITDA margin23.2%, vs 28.8% in Q2 FY25
EBITDA from operations199.6 crore, -18.5% YoY; margin 21.9%, -556 bps YoY
EBIT from operations83 crore, -38.0% YoY; margin 9.1%, -591 bps YoY
Reported PAT (before exceptional items)₹67 Cr, -37% YoY; margin 7.3%
PAT67.1 crore, -36.7% YoY; margin 7.3%, -444 bps YoY
Staff costs307.5 crore, 33.8% of revenue from operations, -331 bps YoY
Foreign exchange fluctuation loss, net11.8 crore, vs gain of 4.3 crore in Q2 FY25
Depreciation and amortisation116.5 crore, +5.1% YoY
Finance costs13.2 crore, +0.4% YoY
H1 FY26 revenue from operations₹1,785 Cr, +6% YoY
H1 FY26 reported EBITDA margin24.1%, vs 26.2% in H1 FY25
H1 FY26 reported PAT (before exceptional items)₹154 Cr, -4% YoY; margin 8.5%
Full-year FY26 revenue guidanceMaintained
Full-year FY26 EBITDA and PAT margin guidanceMaintained
Unrecoverable receivables written off₹27.7 Cr net (₹20.2 Cr after tax), due to cumulative FX rate changes
Capitalised biologics manufacturing assets (Unit 3)₹343.8 Cr, resulting in additional depreciation of ₹7 Cr in Q2 FY26